Journal
INTERNATIONAL JOURNAL OF UROLOGICAL NURSING
Volume 3, Issue 3, Pages 85-92Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1749-771X.2009.01081.x
Keywords
Androgen deprivation; Degarelix; Gonadotrophin-receptor blocker; Hormonal therapy; Prostate cancer
Categories
Funding
- Ferring Pharmaceuticals
Ask authors/readers for more resources
The development of GnRH blockers provides a new class of hormonal agent with a different, direct mode of action. Degarelix, a newly approved GnRH blocker, has displayed a fast, profound and sustained suppression of testosterone and prostate-specific antigen levels without subsequent tumour flare effects. This paper considers the current evidence for this new treatment approach and how this may impact on current urology nursing practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available